SIRT3 in Cardiac Physiology and Disease

Frontiers in Cardiovascular Medicine

Volumn 3, Issue , 2016, Pages

  Koentges, Christoph ^a   Bode, Christoph ^a   Bugger, Heiko ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

heart failure; ischemia reperfusion injury; mitochondria; sirtuin 3

Indexed keywords

EID: 85021147470     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2016.00038     Document Type: Review

References (95)

1. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev (1999) 13(19):2570–80.10.1101/gad.13.19.257010521401
2. Zhang J, Sprung R, Pei J, Tan X, Kim S, Zhu H, et al. Lysine acetylation is a highly abundant and evolutionarily conserved modification in Escherichia coli. Mol Cell Proteomics (2009) 8(2):215–25.10.1074/mcp.M800187-MCP20018723842
3. North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 5(5):224.10.1186/gb-2004-5-5-22415128440
4. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, et al. Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. J Biol Chem (2002) 277(21):18881–90.10.1074/jbc.M11177320011884393
5. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Jr Suthammarak W, Gong G, et al. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab (2013) 18(2):239–50.10.1016/j.cmet.2013.07.00223931755
6. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science (2000) 289(5487):2126–8.10.1126/science.289.5487.212611000115
7. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 27(24):8807–14.10.1128/MCB.01636-0717923681
8. Bugger H, Witt CN, Bode C. Mitochondrial sirtuins in the heart. Heart Fail Rev (2016) 21(5):519.10.1007/s10741-016-9570-7
9. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell (2006) 23(4):607–18.10.1016/j.molcel.2006.06.02616916647
10. Hebert AS, Dittenhafer-Reed KE, Yu W, Bailey DJ, Selen ES, Boersma MD, et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell (2013) 49(1):186–99.10.1016/j.molcel.2012.10.02423201123
11. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A (2006) 103(27):10230–5.10.1073/pnas.060439210316790548
12. Fernandes J, Weddle A, Kinter CS, Humphries KM, Mather T, Szweda LI, et al. Lysine acetylation activates mitochondrial aconitase in the heart. Biochemistry (2015) 54(25):4008–18.10.1021/acs.biochem.5b0037526061789
13. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) (2010) 2(12):914–23.10.18632/aging.10025221212461
14. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol (2008) 382(3):790–801.10.1016/j.jmb.2008.07.04818680753
15. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol (2008) 28(20):6384–401.10.1128/MCB.00426-0818710944
16. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature (2010) 464(7285):121–5.10.1038/nature0877820203611
17. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest (2009) 119(9):2758–71.10.1172/JCI3916219652361
18. Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol (2013) 304(8):H1103–13.10.1152/ajpheart.00636.201223396452
19. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry (2010) 49(2):304–11.10.1021/bi901627u20000467
20. Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One (2011) 6(8):e23295.10.1371/journal.pone.002329521858060
21. Bharathi SS, Zhang Y, Mohsen AW, Uppala R, Balasubramani M, Schreiber E, et al. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. J Biol Chem (2013) 288(47):33837–47.10.1074/jbc.M113.51035424121500
22. Koentges C, Pfeil K, Meyer-Steenbuck M, Lother A, Hoffmann MM, Odening KE, et al. Preserved recovery of cardiac function following ischemia-reperfusion in mice lacking SIRT3. Can J Physiol Pharmacol (2016) 94(1):72–80.10.1139/cjpp-2015-015226524632
23. Koentges C, Pfeil K, Schnick T, Wiese S, Dahlbock R, Cimolai MC, et al. SIRT3 deficiency impairs mitochondrial and contractile function in the heart. Basic Res Cardiol (2015) 110(4):36.10.1007/s00395-015-0493-625962702
24. Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res (2014) 103(4):485–97.10.1093/cvr/cvu15624966184
25. Chen T, Liu J, Li N, Wang S, Liu H, Li J, et al. Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD. PLoS One (2015) 10(3):e0118909.10.1371/journal.pone.011890925748450
26. Porter GA, Urciuoli WR, Brookes PS, Nadtochiy SM. SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol (2014) 306(12):H1602–9.10.1152/ajpheart.00027.201424748594
27. Cheung KG, Cole LK, Xiang B, Chen K, Ma X, Myal Y, et al. Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes. J Biol Chem (2015) 290(17):10981–93.10.1074/jbc.M114.60796025759382
28. Zeng H, Vaka VR, He X, Booz GW, Chen JX. High-fat diet induces cardiac remodelling and dysfunction: assessment of the role played by SIRT3 loss. J Cell Mol Med (2015) 19(8):1847–56.10.1111/jcmm.1255625782072
29. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem (2010) 285(5):3133–44.10.1074/jbc.M109.07727119940131
30. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev (2005) 85(3):1093–129.10.1152/physrev.00006.200415987803
31. Neubauer S. The failing heart – an engine out of fuel. N Engl J Med (2007) 356(11):1140–51.10.1056/NEJMra063052
32. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta (2007) 1767(8):1007–31.10.1016/j.bbabio.2007.05.00817631856
33. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion – a target for cardioprotection. Cardiovasc Res (2004) 61(3):372–85.10.1016/S0008-6363(03)00533-9
34. Schwarz K, Siddiqi N, Singh S, Neil CJ, Dawson DK, Frenneaux MP. The breathing heart – mitochondrial respiratory chain dysfunction in cardiac disease. Int J Cardiol (2014) 171(2):134–43.10.1016/j.ijcard.2013.12.014
35. Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, et al. Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail (2013) 15(2):150–7.10.1093/eurjhf/hfs17223115323
36. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol (2011) 301(6):H2181–90.10.1152/ajpheart.00554.201121949114
37. Zeng L, Yang Y, Hu Y, Sun Y, Du Z, Xie Z, et al. Age-related decrease in the mitochondrial sirtuin deacetylase Sirt3 expression associated with ROS accumulation in the auditory cortex of the mimetic aging rat model. PLoS One (2014) 9(2):e88019.10.1371/journal.pone.008801924505357
38. Martin-Fernandez B, Gredilla R. Mitochondria and oxidative stress in heart aging. Age (Dordr) (2016).10.1007/s11357-016-9933-y27449187
39. Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun (2015) 6:6656.10.1038/ncomms765625871545
40. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A (2008) 105(38):14447–52.10.1073/pnas.080379010518794531
41. Liang L, Li Q, Huang L, Li D, Li X. Sirt3 binds to and deacetylates mitochondrial pyruvate carrier 1 to enhance its activity. Biochem Biophys Res Commun (2015) 468(4):807–12.10.1016/j.bbrc.2015.11.03626577410
42. Sahar S, Nin V, Barbosa MT, Chini EN, Sassone-Corsi P. Altered behavioral and metabolic circadian rhythms in mice with disrupted NAD+ oscillation. Aging (Albany NY) (2011) 3(8):794–802.10.18632/aging.10036821937766
43. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell (2010) 40(6):893–904.10.1016/j.molcel.2010.12.01321172655
44. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab (2010) 12(6):662–7.10.1016/j.cmet.2010.11.01521109198
45. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 2(6):456–62.10.1007/s13238-011-1063-921748595
46. Bao J, Scott I, Lu Z, Pang L, Dimond CC, Gius D, et al. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic Biol Med (2010) 49(7):1230–7.10.1016/j.freeradbiomed.2010.07.00920647045
47. Pillai VB, Bindu S, Sharp W, Fang YH, Kim G, Gupta M, et al. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. Am J Physiol Heart Circ Physiol (2016) 310(8):H962–72.10.1152/ajpheart.00832.201526873966
48. Grillon JM, Johnson KR, Kotlo K, Danziger RS. Non-histone lysine acetylated proteins in heart failure. Biochim Biophys Acta (2012) 1822(4):607–14.10.1016/j.bbadis.2011.11.01622155497
49. Parodi-Rullan R, Barreto-Torres G, Ruiz L, Casasnovas J, Javadov S. Direct renin inhibition exerts an anti-hypertrophic effect associated with improved mitochondrial function in post-infarction heart failure in diabetic rats. Cell Physiol Biochem (2012) 29(5–6):841–50.10.1159/00017852622613984
50. Zeng H, He X, Hou X, Li L, Chen JX. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol (2014) 306(4):H585–97.10.1152/ajpheart.00821.201324363305
51. Hou X, Zeng H, He X, Chen JX. Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes. J Cell Mol Med (2015) 19(1):53–61.10.1111/jcmm.1245325311234
52. Vazquez EJ, Berthiaume JM, Kamath V, Achike O, Buchanan E, Montano MM, et al. Mitochondrial complex I defect and increased fatty acid oxidation enhance protein lysine acetylation in the diabetic heart. Cardiovasc Res (2015) 107(4):453–65.10.1093/cvr/cvv18326101264
53. Sultana MR, Bagul PK, Katare PB, Anwar S, Padiya R, Banerjee SK. Garlic activates SIRT-3 to prevent cardiac oxidative stress and mitochondrial dysfunction in diabetes. Life Sci (2016) 164:42–51.10.1016/j.lfs.2016.08.03027590611
54. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One (2010) 5(7):e11707.10.1371/journal.pone.001170720661474
55. Shi L, Zhang T, Zhou Y, Zeng X, Ran L, Zhang Q, et al. Dihydromyricetin improves skeletal muscle insulin sensitivity by inducing autophagy via the AMPK-PGC-1alpha-Sirt3 signaling pathway. Endocrine (2015) 50(2):378–89.10.1007/s12020-015-0599-5
56. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res (2010) 88(2):229–40.10.1093/cvr/cvq23920639213
57. Tao L, Bei Y, Zhang H, Xiao J, Li X. Exercise for the heart: signaling pathways. Oncotarget (2015) 6(25):20773–84.10.18632/oncotarget.477026318584
58. Sundaresan NR, Bindu S, Pillai VB, Samant S, Pan Y, Huang JY, et al. SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycogen synthase kinase 3beta. Mol Cell Biol (2015) 36(5):678–92.10.1128/MCB.00586-15
59. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev (2007) 25(3):235–60.10.1111/j.1527-3466.2007.00018.x17919258
60. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 130(6):1095–107.10.1016/j.cell.2007.07.03517889652
61. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med (2007) 357(11):1121–35.10.1056/NEJMra071667
62. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 123(1):92–100.10.1172/JCI6287423281415
63. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem (2001) 276(4):2571–5.10.1074/jbc.M00682520011073947
64. Korzick DH, Lancaster TS. Age-related differences in cardiac ischemia-reperfusion injury: effects of estrogen deficiency. Pflugers Arch (2013) 465(5):669–85.10.1007/s00424-013-1255-723525672
65. Lesnefsky EJ, Gallo DS, Ye J, Whittingham TS, Lust WD. Aging increases ischemia-reperfusion injury in the isolated, buffer-perfused heart. J Lab Clin Med (1994) 124(6):843–51.7798799
66. Fannin SW, Lesnefsky EJ, Slabe TJ, Hassan MO, Hoppel CL. Aging selectively decreases oxidative capacity in rat heart interfibrillar mitochondria. Arch Biochem Biophys (1999) 372(2):399–407.10.1006/abbi.1999.150810600182
67. Judge S, Jang YM, Smith A, Hagen T, Leeuwenburgh C. Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of aging. FASEB J (2005) 19(3):419–21.10.1096/fj.04-2622fje15642720
68. Karbowski M, Kurono C, Wozniak M, Ostrowski M, Teranishi M, Nishizawa Y, et al. Free radical-induced megamitochondria formation and apoptosis. Free Radic Biol Med (1999) 26(3–4):396–409.10.1016/S0891-5849(98)00209-39895232
69. Sachs HG, Colgan JA, Lazarus ML. Ultrastructure of the aging myocardium: a morphometric approach. Am J Anat (1977) 150(1):63–71.10.1002/aja.1001500105930852
70. Sohal RS, Dubey A. Mitochondrial oxidative damage, hydrogen peroxide release, and aging. Free Radic Biol Med (1994) 16(5):621–6.10.1016/0891-5849(94)90062-08026805
71. Sohal RS, Ku HH, Agarwal S, Forster MJ, Lal H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech Ageing Dev (1994) 74(1–2):121–33.10.1016/0047-6374(94)90104-X7934203
72. Wang XQ, Shao Y, Ma CY, Chen W, Sun L, Liu W, et al. Decreased SIRT3 in aged human mesenchymal stromal/stem cells increases cellular susceptibility to oxidative stress. J Cell Mol Med (2014) 18(11):2298–310.10.1111/jcmm.1239525210848
73. Kwon Y, Kim J, Lee CY, Kim H. Expression of SIRT1 and SIRT3 varies according to age in mice. Anat Cell Biol (2015) 48(1):54–61.10.5115/acb.2015.48.1.5425806122
74. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell (2013) 155(7):1624–38.10.1016/j.cell.2013.11.03724360282
75. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell (2013) 154(2):430–41.10.1016/j.cell.2013.06.01623870130
76. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 14(4):528–36.10.1016/j.cmet.2011.08.01421982712
77. Averett C, Arora S, Zubair H, Singh S, Bhardwaj A, Singh AP. Molecular targets of Honokiol: a promising phytochemical for effective cancer management. Enzymes (2014) 36:175–93.10.1016/B978-0-12-802215-3.00009-427102704
78. Kumar A, Kumar Singh U, Chaudhary A. Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities. Future Med Chem (2013) 5(7):809–29.10.4155/fmc.13.3223651094
79. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta (2015) 1852(6):1155–77.10.1016/j.bbadis.2014.10.01625451966
80. Han G, Xia J, Gao J, Inagaki Y, Tang W, Kokudo N. Anti-tumor effects and cellular mechanisms of resveratrol. Drug Discov Ther (2015) 9(1):1–12.10.5582/ddt.2015.0100725788047
81. Chen T, Li J, Liu J, Li N, Wang S, Liu H, et al. Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-beta/Smad3 pathway. Am J Physiol Heart Circ Physiol (2015) 308(5):H424–34.10.1152/ajpheart.00454.2014
82. Lee CF, Chavez JD, Garcia-Menendez L, Choi Y, Roe ND, Chiao YA, et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation (2016) 134(12):883–94.10.1161/CIRCULATIONAHA.116.02249527489254
83. Yamamoto T, Byun J, Zhai P, Ikeda Y, Oka S, Sadoshima J. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One (2014) 9(6):e98972.10.1371/journal.pone.009897224905194
84. Gertz M, Steegborn C. Using mitochondrial sirtuins as drug targets: disease implications and available compounds. Cell Mol Life Sci (2016) 73(15):2871–96.10.1007/s00018-016-2180-727007507
85. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 126(5):941–54.10.1016/j.cell.2006.06.05716959573
86. Laurent G, German NJ, Saha AK, de Boer VC, Davies M, Koves TR, et al. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell (2013) 50(5):686–98.10.1016/j.molcel.2013.05.01223746352
87. Mathias RA, Greco TM, Oberstein A, Budayeva HG, Chakrabarti R, Rowland EA, et al. Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity. Cell (2014) 159(7):1615–25.10.1016/j.cell.2014.11.04625525879
88. Luo YX, Tang X, An XZ, Xie XM, Chen XF, Zhao X, et al. Sirt4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J (2016).10.1093/eurheartj/ehw13827099261
89. Liu B, Che W, Xue J, Zheng C, Tang K, Zhang J, et al. SIRT4 prevents hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Cell Physiol Biochem (2013) 32(3):655–62.10.1159/00035446924029877
90. Verma M, Shulga N, Pastorino JG. Sirtuin-4 modulates sensitivity to induction of the mitochondrial permeability transition pore. Biochim Biophys Acta (2013) 1827(1):38–49.10.1016/j.bbabio.2012.09.01623044393
91. Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, et al. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab (2013) 18(6):920–33.10.1016/j.cmet.2013.11.01324315375
92. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics (2011) 10(12):M111012658.10.1074/mcp.M111.01265821908771
93. Sadhukhan S, Liu X, Ryu D, Nelson OD, Stupinski JA, Li Z, et al. Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function. Proc Natl Acad Sci U S A (2016) 113(16):4320–5.10.1073/pnas.151985811327051063
94. Boylston JA, Sun J, Chen Y, Gucek M, Sack MN, Murphy E. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury. J Mol Cell Cardiol (2015) 88:73–81.10.1016/j.yjmcc.2015.09.00526388266
95. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature (2014) 515(7527):431–5.10.1038/nature1390925383517